 |
|
|
| |
No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Waziry R1, Hajarizadeh B1, Grebely J1, Amin J2, Law M1, Danta M3, George J4, Dore GJ1
1The Kirby Institute, UNSW Sydney, Sydney, Australia, 2 Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia, 3St Vincent's Clinical School, UNSW Sydney, Australia 4Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Sydney, Australia.
EASL: Delisting of liver transplant candidates with chronic HCV infection after viral eradication and outcome after delisting. A European cohort study - (04/25/17)
EASL: Early occurrence of hepatocellular carcinoma in patients with HCV cirrhosis treated with direct acting antivirals - (04/24/17)
EASL: Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy - (04/24/17)
EASL: Nivolumab in Sorafenib-Experienced Patients With Advanced Hepatocellular Carcinoma With or Without Chronic Viral Hepatitis: CheckMate 040 Study - (04/21/17)
|
| |
|
|
|
|
|
